Servier Russia is located in Moscow and has been in operation since 2007. The site has one production unit that is dedicated to dry forms manufacturing.
Regulatory affairs activities are essential components of any drug development and commercialization program. CDMOs with extensive experience with product approvals that have regulatory affairs deeply integrated with other operational teams can provide optimized regulatory strategies.
The pharmaceutical industry must respond to growing expectations for product safety, the conduct of clinical trials, access to therapeutic care and the environmental impact of medicinal products and manufacturing. Servier Group formalized its Corporate Social Responsibility (CSR) strategy to integrate and communicate the actions it is taking in collaboration with internal and external stakeholders.
Servier Group is proud to announce that it will develop its presence in the US market through the oncology therapeutic area. Servier CDMO, in accordance with the group’s strategy, continues to develop its services for High Potent drugs in API and drug product.